Technology area: Biotechnology & Pharmaceuticals
26 pending office actions • 21 art units • 26 examiners • 0 of 26 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. has 26 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a distinct examiner, and the docket spans 21 distinct art units. This indicates broad dispersion across examination resources, with no single examiner carrying a substantial portion of the pending work.
WARD, PAUL V is the busiest examiner, with 1 pending matter. Because examiner concentration is minimal, portfolio management should emphasize matter-level tracking and art-unit-specific prosecution decisions. Counsel may find greater value in identifying recurring biotechnology claim issues across cases than in developing a response playbook centered on one examiner.
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (15%) |
| §103 only | 4 (15%) |
| §102 only | 1 (4%) |
| §112 only | 3 (12%) |
| Double-patenting + other | 1 (4%) |
| Multi-statute (no §101) | 13 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| WRIGHT, SARAH C | 1 | 42.1% | +45.6% |
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
| MILLER, DALE R | 1 | 62.5% | +17.6% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
| O'HERN, BRENT T | 1 | 78.5% | +19.4% |
| WRIGHT, ERIC BRANDON | 1 | 0.0% | +0.0% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.8% | +31.5% |
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259836 | STABLE EFFICIENT COSMETIC PREPARATIONS | CHANG, KYUNG SOOK | 160d overdue |
| 18007152 | INJECTION MOLDING OF MEAT-LIKE FOOD PRODUCTS | BECKER, DREW E | 119d overdue |
| 17765625 | LIPOSOMAL CANNABINOIDS AND USES THEREOF | MITCHELL, EDWIN COLEMAN | 98d overdue |
| 18252484 | DECELLULARIZED TISSUE/POLYMER MULTI-COMPONENT BIOMATERIALS | SPENCER, MAXIMILIAN TOBIAS | 38d overdue |
| 18368070 | METHODS AND COMPOSITIONS FOR IN-VITRO AUGMENTATION OF MILK PRODUCTION FROM MAMMARY EPITHELIAL CELLS | NGUYEN, NGHI V | 35d |
| 18624587 | PROTECTIVE COATING FOR PLANTS AND POSTHARVEST PLANT MATTER | O'HERN, BRENT T | 75d |
| 18559809 | PEROVSKITE COMPOSITIONS AND USES THEREOF IN PHOTOVOLTAIC DEVICES | TRIVISONNO, ANGELO | 83d |
| 18833008 | METAP2 INHIBITORS AND USES THEREOF | WARD, PAUL V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18746146 | FORMULATION AND METHOD FOR INCREASING ORAL BIOAVAILABILITY OF DRUGS | WRIGHT, SARAH C | 34d |
| 18624587 | PROTECTIVE COATING FOR PLANTS AND POSTHARVEST PLANT MATTER | O'HERN, BRENT T | 75d |
| 18746141 | NOMADIC BACTERIA AND USES THEREOF | ARMATO JR, DENNIS IGNATIUS | — |
| 18718915 | CARDIAC STEROID DERIVATIVES | MILLER, DALE R | — |
| 18699294 | ARYLATED FENCHONE DERIVATIVES, COMPOSITIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | TOWNSLEY, SARA ELIZABETH | — |
| 18576379 | COMPOUNDS AND USES THEREOF IN THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS ASSOCIATE WITH OR AGGRAVATED BY IMPAIRED MITOPHAGY OR OXIDATIVE STRESS | BARSKY, JARED | — |
| 18563900 | DIAGNOSIS OF AUTISM SPECTRUM DISORDER BY MULTIOMICS PLATFORM | BERKE-SCHLESSEL, DAVID W | — |
| 18290220 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| 1619 | 2 |
| 1651 | 2 |
| 1632 | 2 |
| 1624 | 2 |
| 1693 | 1 |
| 1793 | 1 |
| 1628 | 1 |
| 1629 | 1 |
| 1722 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833008 | METAP2 INHIBITORS AND USES THEREOF | WARD, PAUL V | 1622 | §102§112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18746146 | FORMULATION AND METHOD FOR INCREASING ORAL BIOAVAILABILITY OF DRUGS | WRIGHT, SARAH C | 1619 | §103 | Non-Final OA | 34d | Pending | Jun 18, 2024 |
| 18746141 | NOMADIC BACTERIA AND USES THEREOF | ARMATO JR, DENNIS IGNATIUS | 1651 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18718915 | CARDIAC STEROID DERIVATIVES | MILLER, DALE R | 1693 | §102§103 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18699294 | ARYLATED FENCHONE DERIVATIVES, COMPOSITIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | TOWNSLEY, SARA ELIZABETH | 1622 | §102§103§112 | Non-Final OA | — | Pending | Apr 07, 2024 |
| 18624587 | PROTECTIVE COATING FOR PLANTS AND POSTHARVEST PLANT MATTER | O'HERN, BRENT T | 1793 | §102§103§112 | Non-Final OA | 75d | Pending | Apr 02, 2024 |
| 18598152 | CARDIAC ORGANOID AND ANTI-ELECTRO-MITOCHONDRIAL DESYNCHRONIZATION THERAPY | WRIGHT, ERIC BRANDON | 1632 | §101§102 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18576379 | COMPOUNDS AND USES THEREOF IN THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS ASSOCIATE WITH OR AGGRAVATED BY IMPAIRED MITOPHAGY OR OXIDATIVE STRESS | BARSKY, JARED | 1628 | §112 | Final Rejection | — | Pending | Jan 04, 2024 |
| 18563900 | DIAGNOSIS OF AUTISM SPECTRUM DISORDER BY MULTIOMICS PLATFORM | BERKE-SCHLESSEL, DAVID W | 1651 | §112 | Non-Final OA | — | Pending | Nov 23, 2023 |
| 18290220 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | SEITZ, ANTHONY JOSEPH | 1629 | §102§112 | Final Rejection | — | Pending | Nov 10, 2023 |
| 18559809 | PEROVSKITE COMPOSITIONS AND USES THEREOF IN PHOTOVOLTAIC DEVICES | TRIVISONNO, ANGELO | 1722 | §102§103§112 | Final Rejection | 83d | Pending | Nov 09, 2023 |
| 18286618 | MRI BASED SYSTEM AND METHOD FOR DETECTING IRON-RELATED ENTITIES IN A REGION OF INTEREST | HOFFA, ANGELA MARIE | 3799 | §103 | Final Rejection | 77d overdue | Pending | Oct 12, 2023 |
| 18554199 | THERAPEUTIC MODALITIES FOR INHIBITING PANCREATIC BETA CELL IMPAIRMENT AND TREATING DIABETES | HABTE, KAHSAY | 1624 | §102 | Final Rejection | — | Pending | Oct 05, 2023 |
| 18368070 | METHODS AND COMPOSITIONS FOR IN-VITRO AUGMENTATION OF MILK PRODUCTION FROM MAMMARY EPITHELIAL CELLS | NGUYEN, NGHI V | 1653 | §102§103§112Other | Final Rejection | 35d | Pending | Sep 14, 2023 |
| 18259836 | STABLE EFFICIENT COSMETIC PREPARATIONS | CHANG, KYUNG SOOK | 1613 | §102§103 | Non-Final OA | 160d overdue | Pending | Jun 29, 2023 |
| 18253146 | EXTREMELY FAST SOLID PHASE SYNTHESIS | VARADARAJ, ARCHANA | 1658 | §103DP | Non-Final OA | 14d | Pending | May 16, 2023 |
| 18252484 | DECELLULARIZED TISSUE/POLYMER MULTI-COMPONENT BIOMATERIALS | SPENCER, MAXIMILIAN TOBIAS | 3774 | §102§103 | Final Rejection | 38d overdue | Pending | May 10, 2023 |
| 18251427 | MODIFIED CARBON-BASED MATERIALS | HENDRICKSON, STUART L | 1736 | §102§103§112 | Non-Final OA | — | Pending | May 02, 2023 |
| 18020734 | METHOD FOR THE TREATMENT OF WWOX ASSOCIATED DISEASES | BATES, KEENAN ALEXANDER | 1631 | §103 | Non-Final OA | — | Pending | Feb 10, 2023 |
| 18007152 | INJECTION MOLDING OF MEAT-LIKE FOOD PRODUCTS | BECKER, DREW E | 1792 | §103§112 | Final Rejection | 119d overdue | Pending | Jan 27, 2023 |
| 18004673 | METHODS OF DETERMINING CANCER THERAPY | NEGIN, RUSSELL SCOTT | 1686 | §101§103§112 | Non-Final OA | — | Pending | Jan 08, 2023 |
| 17765625 | LIPOSOMAL CANNABINOIDS AND USES THEREOF | MITCHELL, EDWIN COLEMAN | 1619 | §103§112 | Non-Final OA | 98d overdue | Pending | Mar 31, 2022 |
| 17634414 | PHYTOCANNABINOIDS FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE, DYSLIPIDEMIA, AND TYPE 2 DIABETES | BRAUN, MADELINE E | 1624 | §112 | Non-Final OA | — | Pending | Feb 10, 2022 |
| 17597878 | ANTICANCER AGENTS | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | 70d overdue | Pending | Jan 27, 2022 |
| 17427405 | NEOANTIGENS CREATED BY ABERRANT-INDUCED SPLICING AND USES THEREOF IN ENHANCING IMMUNOTHERAPY | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Final Rejection | — | Pending | Jul 30, 2021 |
| 17051363 | METHOD FOR SELECTING PATIENT SPECIFIC THERAPY | AUGER, NOAH ANDREW | 1687 | §101§112 | Final Rejection | — | Pending | Oct 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYissum Research Development Company of the Hebrew University of Jerusalem Ltd. has 26 pending office actions as of October 2026, spread across 21 art units and 26 examiners.
Paul V Ward has the most, with 1 of Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
